Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAVvlWjDH2QPmr1IMWvFw6HaRS36v4Et_2vIrLQjsNM4c#assertion>. }
Showing items 1 to 10 of
10
with 100 items per page.
- association type Statement assertion.
- association label "iressa is indicated for the first line treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test see clinical studies 14 limitation of use safety and efficacy of iressa have not been established in patients with metastatic nsclc whose tumors have egfr mutations other than exon 19 deletions or exon 21 l858r substitution mutations see clinical studies 14 iressa is a tyrosine kinase inhibitor indicated for the first line treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test 1 limitation of use safety and efficacy of iressa have not been established in patients whose tumors have egfr mutations other than exon 19 deletions or exon 21 l858r substitution mutations 1" assertion.
- association subject drugbank:DB00317 assertion.
- association predicate treats assertion.
- association object DOID_3908 assertion.
- association relation TreatmentIndication assertion.
- drugbank:DB00317 category Drug assertion.
- DOID_3908 category Disease assertion.
- association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
- association provided_by NeuroDKG assertion.